2026 Emerging Topic Conference: Unified Frontiers in Liver Disease — Treating Steatosis, Cholestasis, and Beyond

Evolving Insights into Cholestatic Liver Disease Therapies and Methods to Disentangle Etiopathogensis

Session 1: A New Therapeutic Era in Cholestatic Liver Disease Could Improve the Patient Experience and Outcomes (Part 1)

Moderators: Cynthia Levy & Alan Bonder

8:00 a.m.
Immunological Landscape of PBC: Where Are We Coming From and Where Are We Going? | Vincenzo Ronca

8:20 a.m.
Current Treatment Landscape of Primary Biliary Cholangitis (PBC) | Aparna Goel

8:40 a.m.
Are We Ready for a Personalized Approach to PBC? | Cynthia Levy

9:00 a.m.
Disentangling the Overlap Syndromes (PBC and PSC + AIH/MASLD): From Diagnosis to New Treatments | Marilyn Mayo 

9:20 a.m.
Panel Discussion / Q&A

9:40 a.m.
Break

Session 2: A New Therapeutic Era in Cholestatic Liver Disease Could Improve the Patient Experience and Outcomes (Part 2) 

Moderators: David Assis & Sonya MacParland

10:00 a.m.
Immunobiologic Landscape of PSC: A Continuum of Time and Space | Martin Cornillet

10:20 a.m.
Emerging Therapies and Mechanisms in PSC | David Assis

10:40 a.m.
Deep Learning in PBC and PSC: Diagnosis and Prediction of Outcomes | John Eaton

11:00 a.m.
Oral Abstract Presentations: 2 (10 min) talks - Clinical Connections in PSC/PBC    
TBD

11:20 a.m.
Panel Discussion / Q&A    

11:40 a.m.        
TABLETOP EXPO (35 minutes)

12:15 a.m.            
Lunch w/optional industry symposium

Session 3: Methodologic Innovation Provides New Clues to Cholestatic Liver Disease Pathogenesis and Treatments (Part 1)

Moderators: Pietro Invernizzi & Marilyn Mayo

1:15 p.m.
Navigating the Drug Development Challenges of PBC in the Post-Marketing World | Alan Bonder

1:35 p.m.
Lessons from Epigenetic (EWAS) Changes in PSC and PBC | Pietro Invernizzi

1:55 p.m.
New Concepts on Pathophysiology and Treatment of Pruritus and Fatigue in Cholestatic Liver Diseases | Mark Swain

2:15 p.m.
Genetic Underpinnings to Cholestatic Liver Disease | Silvia Vilarinho

2:35 p.m.
Panel Discussion / Q&A            

2:55 p.m.
Break    

Session 4: Methodologic Innovation Provides New Clues to Cholestatic Liver Disease Pathogenesis and Treatments (Part 2)

Moderators: Michael Trauner & Craig Lammert

3:15 p.m.
Single Cell Sequencing and Immunologic Insights in Cholestasis | Sonya MacParland 

3:35 p.m.
Bile Acid Signaling in Cholestasis and Therapeutic Implications | Michael Trauner 

3:55 p.m.
Extrahepatic Cholangiocyte Organoids (Microphysiologic Systems) for Cholestatic Disease Modeling | Ana Garcia Moreno 

4:15 p.m.
Oral Abstract Presentations: 2 (10 min) talks - Translational Connections in PSC/PBC
TBD

5:00 p.m.
Welcome Reception and Poster Presentation Showcase — Open to All Registered Attendees

6:30 p.m.
Day 1 adjourned

Steatotic Liver Disease: From Bench to Clinical Care and Public Policy

Session 1: The Science of SLD and Dysmetabolism

Moderators: Mary Rinella and Rotonya Carr

8:00 a.m.
The Role of Metabolic Dysfunction and Alcohol in Steatohepatitis | Rotonya Carr

8:20 a.m.
Understanding the Role of Hunger/Satiety and Addiction Centers in SLD | Samuel Klein        

8:40 a.m.
How Did Our Food and Environment Become Obesogenic in the Last Few Decades? | Ani Kardashian

9:00 a.m.
Antenatal MASH and Obesity – The Role of Maternal Health for the Next Generation | Monika Sarkar        

9:20 a.m.
Panel Discussion / Q&A

9:40 a.m.
Break    

Session 2: Updates in MetALD

Moderators: Mary Rinella and Mazen Noureddin

10:00 a.m.
How Should We Refine MetALD: Updates in Diagnosis and Biomarkers of Alcohol Use | Brian Lee

10:20 a.m.    
Clinical Course of MetALD in the SLD Continuum | Maja Thiele

10:40 a.m.
Treatment Approaches in the Clinic: Examples of Effective Multidisciplinary Care That Include AUD Treatment | Gene Im        

11:00 a.m.
MetALD Trials and Endpoints | JP Arab

11:20 a.m.
Panel Discussion / Q&A    

11:40 a.m.        
TABLETOP EXPO (35 minutes)

12:15 p.m.            
Lunch with industry symposium sponsored by Madrigal Pharmaceuticals
Rezdiffra: Unlocking the potential of a liver-directed treatment

Session 3: Clinical Care Pathways in SLD

Moderators: Meena Bansal and Jay Shubrook 

1:15 p.m.
Screening for SLD in Primary Care - Is This a Realistic Goal? | Jay Shubrook

1:35 p.m.
Decentralizing the Role of PCP Using Digital Hepatology | Alina Allen

1:55 p.m.
Including SLD Screening in USPSTF Recommendations - What Would It Take? | Fasiha Kanwal

2:15 p.m.    
Pros and Cons of Liver Health Screening in Diabetes as a Quality Measure | Meena Bansal

2:35 p.m.
Panel Discussion / Q&A

2:55 p.m.    
Break & Tabletop Expo

Session 4: Patients’ Perspectives and Public Health Approaches

Moderators: Grace Su and Eliott Tapper

3:30 p.m.
Patients’ Perspectives on the Harms and Benefits of Screening for SLD | Jennifer Berg (Patient)

3:50 p.m.
How to Engage with the Congress and General Public to Increase Awareness of SLD | Grace Su

4:10 p.m.
Public Health Measures and Screening Campaigns in SLD - What Can We Learn from Other Fields Such as Obesity or Cardiovascular Disease | Scott Isaacs

4:30 p.m.
The Role of Social Media in Increasing Public Awareness in MASLD and ALD | Eliott Tapper

4:50 p.m.
Panel Discussion/ Q&A

5:10 p.m.
Day 2 adjourned

Steatotic Liver Disease: From Bench to Clinical Care and Public Policy

Session 5: SLD Treatment and Prevention

Moderators: Naim Alkhouri and Meena Bansal

8:00 a.m.
Review Trial Effectiveness of Currently Approved Medications for SLD and Obesity | Rohit Loomba

8:20 a.m.
Real-World Experience with Resmetirom and GLP-1 Agents After Approval | Naim Alkhouri

8:40 a.m.
Decreasing the Burden of SLD with Preventive Hepatology | Pere Gines

9:00 a.m.
Current Randomized Controlled Trials in SLD | Mazen Noureddin

9:20 a.m.
Panel Discussion

9:40 a.m.
Break

Session 6: Latest Findings in SLD Research (Oral Posters)

Moderators: Alina Allen and Mazen Noureddin

10:00 a.m.
Keynote Lecture: How do we make an impactful change in SLD- from efficient diagnosis to effective care and public health interventions | W. Ray Kim

10:20 a.m.-11:20 a.m.
Poster Presentations: details coming soon.

11:40 a.m. 
Panel Discussion/ Q&A

12:00 p.m.
Day 3 adjourned